September 15, 2016
After completing this activity, participants should be able to:
- Describe the clinical and economic impact of breast cancer in the United States and factors that impact prognosis
- Identify strategies to aid providers in adhering to guidelines and evidence-based recommendations for the diagnosis, treatment, and management of patients with HER2+ breast cancer
- Apply recent clinical/cost data, value-based guidance, and individualized care strategies to formulary and patient access discussions for HER2+ breast cancer
- Differentiate among reference drugs, biosimilars, and generic drugs in terms of their manufacturing processes, clinical considerations, regulatory parameters, interchangeability, safety/efficacy, cost-benefit, and patient impact
Event details available here.